Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J1817
50 UNITS
Medicare payment limit per unit (Q4 2026): $3.116
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 0Not reportable in this setting | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | CMS Policy |
| Facility outpatient hospital services | 0Not reportable in this setting | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | CMS Policy |
| DME supplier services | 270 | 3 Date of Service Edit: Clinical |
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$3.116per 50 UNITS
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 20.000%
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $3.116 | 50 UNITS | 20% | +1.8% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $3.062 | 50 UNITS | 20% | −2.1% |
Medicare hospital outpatient (OPPS) · Q4 2026
N Packaged: no separate payment
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 50090-0352-00 | Humulin NA-S Medication Solutions | 10 × 1 | 20 | 20 | $62.32 | ASP | Q3 2024 – Q4 2026 | Excluded listingHumulin N |
| 50090-0353-00 | Humulin RA-S Medication Solutions | 10 × 1 | 20 | 20 | $62.32 | ASP | Q1 2021 – Q4 2026 | ListedHumulin R |
| 50090-0497-00 | Novolin RA-S Medication Solutions | 10 × 1 | 20 | 20 | $62.32 | ASP | Q3 2024 – Q4 2026 | Excluded listingNovolin R |
| 50090-0498-00 | Novolin NA-S Medication Solutions | 10 × 1 | 20 | 20 | $62.32 | ASP | Q3 2024 – Q4 2026 | Excluded listingNovolin N |
| 50090-1375-00 | HumalogA-S Medication Solutions | 10 × 1 | 20 | 20 | $62.32 | ASP | Q1 2021 – Q4 2026 | ListedHumalog |
| 50090-1664-00 | NovologA-S Medication Solutions | 10 × 1 | 20 | 20 | $62.32 | ASP | Q1 2021 – Q4 2026 | ListedNovolog |
| 50090-1678-00 | Novolog FlexpenA-S Medication Solutions | 3 × 5 | 6 | 30 | $93.48 | ASP | Q1 2021 – Q4 2026 | ListedNovolog |
| 50090-4956-00 | Insulin AspartA-S Medication Solutions | 3 × 5 | 6 | 30 | $93.48 | ASP | Q3 2025 – Q4 2026 | ListedInsulin aspart |
| 50090-5391-00 | Insulin LisproA-S Medication Solutions | 10 × 1 | 20 | 20 | $62.32 | ASP | Q2 2021 – Q4 2026 | ListedInsulin lispro |
| 00002-0213-01 | Humilin REli Lilly and Company | 3 × 1 | 6 | 6 | $18.70 | ASP | Q2 2024 – Q4 2026 | ListedHumulin R |
| 00002-7510-01 | HumalogEli Lilly and Company | 10 × 1 | 20 | 20 | $62.32 | ASP | Q1 2021 – Q4 2026 | ListedHumalog |
| 00002-7510-17 | HumalogEli Lilly and Company | 3 × 1 | 6 | 6 | $18.70 | ASP | Q1 2021 – Q4 2026 | Excluded listingHumalog |
| 00002-7516-59 | HumalogEli Lilly and Company | 3 × 5 | 6 | 30 | $93.48 | ASP | Q1 2021 – Q4 2026 | ListedHumalog |
| 00002-7533-01 | HumalogEli Lilly and Company | 3 × 1 | 6 | 6 | $18.70 | ASP | Q2 2024 – Q4 2026 | Excluded listingHumalog |
| 00002-7737-01 | Insulin LisproEli Lilly and Company | 10 × 1 | 20 | 20 | $62.32 | ASP | Q1 2021 – Q4 2026 | ListedInsulin lispro |
| 00002-7752-05 | Insulin Lispro Junior KwikpenEli Lilly and Company | 3 × 5 | 6 | 30 | $93.48 | ASP | Q1 2021 – Q4 2026 | ListedInsulin Lispro Junior KwikPen |
| 00002-8213-05 | Humalog Tempo PenEli Lilly and Company | 3 × 5 | 6 | 30 | $93.48 | ASP | Q2 2023 – Q4 2026 | ListedHumalog Tempo Pen |
| 00002-8215-01 | Humulin REli Lilly and Company | 10 × 1 | 20 | 20 | $62.32 | ASP | Q1 2021 – Q4 2026 | ListedHumulin R |
| 00002-8215-17 | Humulin REli Lilly and Company | 3 × 1 | 6 | 6 | $18.70 | ASP | Q1 2021 – Q4 2026 | Excluded listingHumulin R |
| 00002-8222-59 | Insulin Lispro KwikpenEli Lilly and Company | 3 × 5 | 6 | 30 | $93.48 | ASP | Q1 2021 – Q4 2026 | ListedInsulin Lispro KwikPen |
| 00002-8501-01 | Humulin REli Lilly and Company | 20 × 1 | 200 | 200 | $623.20 | ASP | Q1 2021 – Q4 2026 | Excluded listingHumulin R U-500 |
| 00002-8799-59 | Humalog KwikpenEli Lilly and Company | 3 × 5 | 6 | 30 | $93.48 | ASP | Q1 2021 – Q4 2026 | ListedHumalog KwikPen |
| 00169-2100-11 | insulin aspartNovo Nordisk, Inc | 10 × 1 | 20 | 20 | $62.32 | ASP | Q4 2021 – Q4 2026 | ListedNovolog |
| 00169-2101-25 | insulin aspartNovo Nordisk, Inc | 3 × 5 | 6 | 30 | $93.48 | ASP | Q4 2021 – Q4 2026 | ListedNovolog |
| 00169-3303-12 | Novolog PenfillNovo Nordisk, Inc | 3 × 5 | 6 | 30 | $93.48 | ASP | Q1 2021 – Q4 2026 | ListedNovolog |
| 00169-6339-10 | Novolog FlexpenNovo Nordisk, Inc | 3 × 5 | 6 | 30 | $93.48 | ASP | Q1 2021 – Q4 2026 | ListedNovolog |
| 00169-7501-11 | NovologNovo Nordisk, Inc | 10 × 1 | 20 | 20 | $62.32 | ASP | Q1 2021 – Q4 2026 | ListedNovolog |
| 00024-5924-10 | AdmelogSanofi-Aventis U.S. LLC | 10 × 1 | 20 | 20 | $62.32 | ASP | Q1 2026 – Q4 2026 | ListedAdmelog |
| 00024-5925-05 | AdmelogSanofi-Aventis U.S. LLC | 3 × 5 | 6 | 30 | $93.48 | ASP | Q1 2026 – Q4 2026 | ListedAdmelog |
| 00024-5926-05 | AdmelogSanofi-Aventis U.S. LLC | 3 × 1 | 6 | 6 | $18.70 | ASP | Q1 2026 – Q4 2026 | ListedAdmelog |
| 00088-2500-33 | ApidraSanofi-Aventis U.S. LLC | 10 × 1 | 20 | 20 | $62.32 | ASP | Q1 2026 – Q4 2026 | ListedApidra |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 66733-0773-01 | Insulin LisproELI LILLY AND COMPANY | 10 × 1 | 20 | 20 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 2003 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| Prescribing Information |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
| — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $3.128 | 50 UNITS | 20% | −2.3% | — |
|---|
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $3.200 | 50 UNITS | 20% | +0.4% | — |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $3.187 | 50 UNITS | 20% | −1.5% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $3.237 | 50 UNITS | 20% | +29.9% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $2.491 | 50 UNITS | 20% | +4.6% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $2.382 | 50 UNITS | 20% | −3.2% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $2.462 | 50 UNITS | 20% | +0.4% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $2.452 | 50 UNITS | 20% | −67.7% | Updated October 2024 |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $7.595 | 50 UNITS | 20% | −4.6% | Updated July 2024 |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $7.959 | 50 UNITS | 20% | −4.1% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $8.302 | 50 UNITS | 20% | −1.7% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $8.442 | 50 UNITS | 20% | −3.4% | Updated July 2024 |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $8.737 | 50 UNITS | 20% | +3.5% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $8.440 | 50 UNITS | — | −0.3% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $8.467 | 50 UNITS | — | +1.9% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $8.311 | 50 UNITS | — | −7.1% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $8.944 | 50 UNITS | — | −18.3% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $10.952 | 50 UNITS | — | −1.7% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $11.138 | 50 UNITS | — | +3.6% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $10.754 | 50 UNITS | — | −0.3% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $10.787 | 50 UNITS | — | −1.0% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $10.897 | 50 UNITS | — | — | — |
|---|
| 66733-0822-59 | INSULIN LISPRO KWIKPENELI LILLY AND COMPANY | 3 × 5 | 6 | 30 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingInsulin Lispro KwikPen |
|---|
| 00169-1833-02 | Novolin RNOVO NORDISK INC | 10 × 1 | 20 | 20 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | ListedNovolin R |
|---|
| 00169-1833-11 | Novolin RNOVO NORDISK INC | 10 × 1 | 20 | 20 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | ListedNovolin R |
|---|
| 00169-2200-11 | Novolog Mix 70/30NOVO NORDISK INC | 10 × 1 | 20 | 20 | ASP | Q1 2022 – Q4 2023Not in Q4 2026 file | ListedNovoLog Mix 70/30 |
|---|
| 00169-2201-25 | Novolog Mix 70/30NOVO NORDISK INC | 3 × 5 | 6 | 30 | ASP | Q1 2022 – Q4 2023Not in Q4 2026 file | ListedNovoLog Mix 70/30 |
|---|
| 00169-3205-15 | Fiasp PenfillNOVO NORDISK INC | 3 × 5 | 6 | 30 | ASP | Q4 2021 – Q3 2022Not in Q4 2026 file | ListedFiasp |
|---|